Solution

Ovarian cancer

Ovarian cancer is the second most common gynecologic malignancy in developed countries and the third most common gynecologic malignancy in developing countries (cervical cancer is the most common) [1].Estimation of cancer antigen 125 (CA125) levels and transvaginal sonography are the best and most frequently recommended methods for diagnosing ovarian cancer [2,3,4]. HE4 and CA72-4 determination is the best approach to confirm the benign nature of ovarian endometrioma in women with high CA125 levels. [5]

Specification


Clinical Significance

CA125

when measured together with other tumoral markers (such as CA19.9 or CEA)CA125 was assessed by numerous investigators regarding its utility as a marker of stage, disease status, prognosis or even in the screening of ovarian cancer. [6]


HE4

HE4 is the most useful marker for the differ-ential diagnosis between EOC and ovarian endometriosis[7]. Different studies propose the use of a Risk of Ovarian Malignancy Algorithm (ROMA) to improve the sensitivity and specificity of the combined use of both HE4 and CA125 in patients with abdominal masses.[8]

CA72-4

CA 72-4 is a tumor marker for gastrointestinal cancer and ovarian cancer. Compared with CA125, the positive rate of CA72-4 is higher in mucinous ovarian cancer. The combination of the two tumor makers can improve the diagnostic sensitivity of ovarian cancer.


References

[1] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65:87.

[2] Daly MB, Pilarski R, Berry MP, Buys SS, Friedman S, Garber JE, et al. NCCN Guidelines Insights: genetic/familial high-risk assessment: breast and ovarian, version 2.2017. J Natl Compr Canc Netw 2017;15:9-20.

[3] Fotopoulou C, Hall M, Cruickshank D, Gabra H, Ganesan R, Hughes C, et al. British Gynaecological Cancer Society (BGCS) epithelial ovarian/Fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. Eur J Obstet Gynecol Reprod Biol 2017;213:123-139.

[4] Committee on Gynecologic Practice, Society of Gynecologic Oncology. Committee Opinion No. 716. Committee Opinion No. 716: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer in women at average risk. Obstet Gynecol 2017;130:e146-e149.

[5]Anastasi, E., Granato, T., Falzarano, R. et al. The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer. J Ovarian Res 6, 44 (2013).

[6]DANIELION,GEORGIANARADU,DANNICOLAEPĂDURARU, OCTAVIAN ANDRONIC, ALEXANDRA BOLOCAN. CA125 and CA242 markers' role in colorectal cancer diagnosis and management–a 30 year review. Romanian Biotechnological Letters 25(5):1977-1983. DOI:10.25083/rbl/25.5/1977.1983

[7]Moore RG, Miller MC, Steinhoff MM, Skates SJ, Lu KH, Lambert-Messerlian G,Bast RC Jr: Serum HE4 levels are less frequently elevated than CA125 inwomen with benign gynecologic disorders. Am J Obstet Gynecol 2012,206(4):351.

[8] Molina R, Escudero JM, Augé JM, Filella X, Foj L, Torné A, Lejarcegui J, Pahisa J. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol. 2011 Dec;32(6):1087-95. doi: 10.1007/s13277-011-0204-3. Epub 2011 Aug 24. PMID: 21863264; PMCID: PMC3195682.

Request a Quote

*
*
*
*
*